Heparanase and vascular endothelial growth factor expression is increased in hypoxia-induced retinal neovascularization

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 11, 2012, Pages 6810-6817

  Hu, Jie ^a   Song, Xin ^a   He, Yi Qing ^b,c   Freeman, Craig ^c   Parish, Christopher R ^c   Yuan, Ling ^a   Yu, Honghua ^a   Tang, Shibo ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c Australian National University   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

COBALT CHLORIDE; HEPARANASE; PI 88; VASCULOTROPIN; BETA GLUCURONIDASE; RNA; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOFLUORESCENCE TEST; MOUSE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RETINA NEOVASCULARIZATION; RETINOPATHY; UPREGULATION; WESTERN BLOTTING; ANIMAL; ANOXIA; BIOSYNTHESIS; C57BL MOUSE; COMPARATIVE STUDY; DISEASE MODEL; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; NEWBORN; PATHOLOGY; RETINA;

ANIMALS; ANIMALS, NEWBORN; ANOXIA; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; GLUCURONIDASE; HUMANS; MALE; MICE; MICE, INBRED C57BL; REAL-TIME POLYMERASE CHAIN REACTION; RETINA; RETINAL NEOVASCULARIZATION; RNA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84871886241     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.11-9144     Document Type: Article

References (32)

1. Chen J, Smith LE. Retinopathy of prematurity. Angiogenesis. 2007;10:133-140.
2. Foos RY. Retinopathy of prematurity. Pathologic correlation of clinical stages. Retina. 1987;7:260-276.
3. Ferrara N, Gerber HP, Lecouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669-676.
4. Aiello LP, Northrup JM, Keyt BA, Takagi H, Iwamoto MA. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol. 1995;113:1538-1544.
5. Robinson GS, Aiello LP. Angiogenic factors in diabetic ocular disease: mechanisms of today, therapies for tomorrow. Int Ophthalmol Clin. 1998;38:89-102.
6. Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol. 1994; 118:445-450.
7. Mintz-Hittner HA, Best LM. Antivascular endothelial growth factor for retinopathy of prematurity. Curr Opin Pediatr. 2009; 21:182-187.
8. Darlow BA, Gilbert C, Quinn GE. Promise and potential pitfalls of anti-VEGF drugs in retinopathy of prematurity. Br J Ophthalmol. 2009;93:986.
9. Nicholson BP, Schachat AP. A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2010;248:915-930.
10. Vreys V, David G. Mammalian heparanase: what is the message? J Cell Mol Med. 2007;11:427-452.
11. Bame KJ. Heparanases: endoglycosidases that degrade heparan sulfate proteoglycans. Glycobiology. 2001;11:91R-98R.
12. Brown J. The hypoxic cell: a target for selective cancer therapy-eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res. 1999;59:5863-5870.
13. He X, Brenchley PE, Jayson GC, Hampson L, Davies J, Hampson IN. Hypoxia increases heparanase-dependent tumor cell invasion, which can be inhibited by antiheparanase antibodies. Cancer Res. 2004;64:3928-3933.
14. Zetser A, Bashenko Y, Edovitsky E, et al. Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. Cancer Res. 2006;66:1455-1463.
15. Vlodavsky I, Ilan N, Naggi A, Casu B. Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr Pharm Res. 2007;13:2057-2073.
16. Li B, Tang SB, Hu J, et al. Protective effects of transcription factor HESR1 on retinal vasculature. Microvasc Res. 2006;72: 146-152.
17. Ryan HE, Poloni M, McNulty W, et al. Hypoxia-inducible factor-1α is a positive factor in solid tumor growth. Cancer Res. 2000;60:4010-4015.
18. Parish CR, Freeman C, Brown KJ, Francis DJ, Cowden WB. Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Res. 1999;59: 3433-3441.
19. Smith LE, Wesolowski E, McLellan A, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994;35: 101-111.
20. Levidiotis V, Freeman C, Punler M, et al. A synthetic heparanase inhibitor reduces proteinuria in passive Heymann nephritis. J Am Soc Nephrol. 2004;15:2882-2892.
21. Parish CR, Freeman C, Brown KJ, Francis DJ, Cowden WB. Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Res. 1999;59: 3433-3441.
22. Kubota Y, Suda T. Feedback mechanism between blood vessels and astrocytes in retinal vascular development. Trends Cardiovasc Med. 2009;19:38-43.
23. Vlodavsky I, Korner G, Ishai-Michaeli R, Bashkin P, Bar-Shavit R, Fuks Z. Extracellular matrix-resident growth factors and enzymes: possible involvement in tumor metastasis and angiogenesis. Cancer Metastasis Rev. 1990;9:203-226.
24. Vlodavsky I, Elkin M, Pappo O, et al. Mammalian heparanase as mediator of tumor metastasis and angiogenesis. Isr Med Assoc J. 2000;2(suppl):37-45.
25. Kudchadkar R, Gonzalez R, Lewis KD. PI-88: a novel inhibitor of angiogenesis. Expert Opin Investig Drugs. 2008;17:1769-1776.
26. Ma PP, Luo Y, Hu J, et al. Retinal heparanase expression in streptozotocin-induced diabetic rats. Can J Ophthalmol. 2010; 45:46-51.
27. Ma PP, Luo Y, Hu J, et al. Phosphomannopentaose sulfate (PI-88) inhibits retinal leukostasis in diabetic rat. Biochem Biophys Res Commun. 2009;380:402-406.
28. Rivera RS, Nagatsuka H, Siar CH, et al. Heparanase and vascular endothelial growth factor expression in the progression of oral mucosal melanoma. Oncol Rep. 2008;19:657-661.
29. Naomoto Y, Gunduz M, Takaoka M, et al. Heparanase promotes angiogenesis through Cox-2 and HIF1alpha. Med Hypotheses. 2007;68:162-165.
30. Santos SC, Miguel C, Domingues I, et al. VEGF and VEGFR-2 (KDR) internalization is required for endothelial recovery during wound healing. Exp Cell Res. 2007;313:1561-1574.
31. Rosenbaum-Dekel Y, Fuchs A, Yakirevich E, et al. Nuclear localization of long-VEGF is associated with hypoxia and tumor angiogenesis. Biochem Biophys Res Commun. 2005; 332:271-278.
32. Domingues I, Rino J, Demmers JA, de Lanerolle P, Santos SC. VEGFR2 translocates to the nucleus to regulate its own transcription. PLoS One. 2011;6:e25668.